Literature DB >> 6490173

Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile.

S Cronberg, B Castor, A Thorén.   

Abstract

Twenty courses of fusidic acid were given to 16 patients with antibiotic-associated colitis caused by Clostridium difficile. Fusidic acid was given in a dose of 0.5-1.5 g daily for seven to 21 days. Diarrhoea disappeared rapidly. Clinical relapse occurred after five courses and once when the patient was still on treatment. Clinical cure with persistence or reappearance of toxin occurred in four further patients. Nineteen courses of metronidazole were given to 19 patients who experienced six failures or relapses. Seven courses of vancomycin were given to five patients, three of whom had had relapse. Five patients healed without treatment. The relapses occurred only in old and prostrated patients. They often recurred several times in the same patient. 0.5 g of fusidic acid daily appears to be as effective as vancomycin and metronidazole for the treatment of C. difficile-induced colitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6490173     DOI: 10.1007/bf01645961

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

2.  Antibiotic susceptibility of Clostridium difficile.

Authors:  D W Burdon; J D Brown; D J Youngs; Y Arabi; N Shinagawa; J Alexander-Williams; M R Keighley; R H George
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

3.  Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin.

Authors:  T W Chang; S L Gorbach; J G Bartlett; R Saginur
Journal:  Gastroenterology       Date:  1980-06       Impact factor: 22.682

4.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

5.  Diagnosis of Clostridium difficile-associated enterocolitis in Sweden. Laboratory and epidemiological aspects.

Authors:  R Möllby; C E Nord; B Aronsson
Journal:  Scand J Infect Dis Suppl       Date:  1980

6.  Treatment of Clostridium difficile colitis and diarrhea with vancomycin.

Authors:  J Silva; D H Batts; R Fekety; J F Plouffe; G D Rifkin; I Baird
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

  6 in total
  7 in total

1.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Clostridium difficile-associated colitis.

Authors:  Mark W Hull; Paul L Beck
Journal:  Can Fam Physician       Date:  2004-11       Impact factor: 3.275

3.  Activity of sodium fusidate in vitro against anaerobic bacteria.

Authors:  M Robbins; R Marais; A P Wilson; D Felmingham
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

4.  Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.

Authors:  T Norén; T Akerlund; M Wullt; L G Burman; M Unemo
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

Review 5.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

6.  New antimicrobial agents for patients with Clostridium difficile infections.

Authors:  John G Bartlett
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

7.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.